PharVision Advisers’s Phibro Animal Health PAHC Stock Holding History

PharVision Advisers’s Portfolio PAHC Stock Details PAHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,881	Closed	-$294K	–	495
2025 Q4	$294K	Buy	+7,881	New	+$320K	0.15%	283

Other funds holding PAHC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PharVision Advisers's PAHC Position: Q1 2026 in Review

PharVision Advisers sold out of Phibro Animal Health (PAHC) in Q1 2026, closing a stake of 7,881 shares — an estimated $294K sold.

PharVision Advisers first reported a position in PAHC in Q4 2025 and held it in 1 quarter. The position peaked at $294K in Q4 2025. 257 funds tracked by Wall St. Rank hold PAHC as of Q1 2026.

PharVision Advisers reported no remaining Phibro Animal Health position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 7,881 Phibro Animal Health shares in Q1 2026, an estimated $294K.
PharVision Advisers first reported a position in Phibro Animal Health in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Phibro Animal Health position peaked at $294K in Q4 2025.
257 funds tracked by Wall St. Rank held Phibro Animal Health as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.